Clene (NASDAQ:CLNN) Stock Rating Reaffirmed as “Buy” by HC Wainwright

Clene (NASDAQ:CLNN)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Monday, Benzinga reports.

Separately, Weiss Ratings upgraded shares of Clene from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.00.

Clene Trading Up 13.4%

NASDAQ:CLNN traded up $0.44 during trading hours on Monday, reaching $3.73. The company had a trading volume of 201,791 shares, compared to its average volume of 220,768. Clene has a 52 week low of $3.02 and a 52 week high of $13.50. The firm has a market cap of $48.45 million, a price-to-earnings ratio of -1.07 and a beta of 0.91. The firm’s 50 day moving average price is $4.00 and its 200-day moving average price is $5.31.

Clene (NASDAQ:CLNN) last issued its quarterly earnings results on Friday, August 14th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.71). The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.06 million. On average, analysts forecast that Clene will post -1.70 earnings per share for the current fiscal year.

About Clene

Clene Inc (NASDAQ: CLNN) is a clinical-stage biopharmaceutical company developing nanotherapeutic medicines for neurodegenerative diseases. The company’s platform uses clean-surfaced nanocrystals designed to influence cellular energy production and support the health and function of nerve cells.

Clene’s lead product candidate is CNM-Au8, an orally administered suspension of gold nanocrystals. The company has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis and Parkinson’s disease, with research focused on potential neuroprotective and remyelinating effects.